Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SELECT-1: Selumetinib + Docetaxel in KRAS+ NSCLC
NCT01933932Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Sep 2013
- Primary completion
- Jun 2016
- Modality
- Small Molecules
- Countries
- 26
01
Overview
A Phase 3 trial of selumetinib in non-small cell lung cancer (NSCLC), sponsored by AstraZeneca. Started Sep 2013; status: active, not recruiting.
02
Drugs
selumetinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01933932.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01933932.